No Data
No Data
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $38
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Pliant Therapeutics (PLRX) and Immunovant (IMVT)
Immunovant Is Maintained at Buy by Guggenheim
Immunovant Price Target Cut to $44.00/Share From $46.00 by Guggenheim